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Background: Health-related quality of life (QOL) is an
important issue in post-transplant care of long-term survi-
vors after hematopoietic stem cell transplantation (HSCT).
We conducted a single-center cross-sectional analysis of
medical and socio-demographic factors affecting on the QOL
outcomes in HSCT recipients.
Patients and Methods: This analysis included 152 Japanese
adult patients surviving more than 2 years after allogeneic
HSCT in Toranomon Hospital, who were enrolled at a median
of 5.4 (2.0-18.4) years from HSCT. Patient-reported QOL was
assessed using two questionnaires (FACT-BMT and SF-36),
and physical exams and laboratory tests for screening post-
transplant complications were principally performed at the
time of QOL survey completion. Chronic graft-versus-host
disease (cGVHD) severity was determined by NIH consensus
criteria. Socio-demographic data was collected through self-
report and chart review.
Results: The median age at enrollment was 55 (23-75) years
old. Thirty-eight patients received related donor grafts, while
58 and 56 received unrelated cord blood and bone marrow.
One hundred received reduced-intensity conditioning.
cGVHD were observed in 127 patients (severe in 17,
moderate in 65, mild in 45), the most commonly involved
organ of which was eyes (51.3%), followed by skin (50%) and
mouth (34.9%). Forty-six patients had other late complica-
tions (endocrine disorders in 9, bone events in 22, ocular
events in 22, and secondary malignancies in 5). The differ-
ences according to interval from HSCT were not seen in all
composite score and subscales of the two questionnaires
except physical well-being score (PWB) of the FACT-BMT
during the late post-transplant period. Although the FACT-
BMT total score was not signiﬁcantly different between
patients who had any cGVHD and those who did not, it
progressively decreased with increasing cGVHD severity and
signiﬁcantly lower for severe cGVHD compared to moderate
cGVHD (P¼ 0.01, Figure 1A). Severe cGVHD had a remarkable
adverse impact on physical aspects of QOL (the physical
component score (PCS) of the SF-36 and PWB, both P < .001,
Figure 1B). Oral, gastrointestinal, musculoskeletal and
pulmonary involvement was strongly associated with poor
QOL. Multivariable logistic regression analysis revealed the
positive impact of employment status on physical and
functional aspects of QOL (PCS: HR 0.41, P ¼ .018 and the
functional well-being score (FWB) of the FACT-BMT: HR 0.27,
P < .001), in addition to the signiﬁcant correlation between
cGVHD severity and the perception of QOL. The FWB was
signiﬁcantly higher in patients with severe cGVHD who had
a work compared to those who did not (P ¼ 0.02).Discussion: The impairment of QOL was particularly prom-
inent among the patients with severe cGVHD. Preventing
severe cGVHD and promoting reintegration into society
might improve overall QOL outcome in long-term survivors
after HSCT.
Figure 1. Quality of life scores according to cGVHD severity.74
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Objective: Increase in the number of hematopoietic stem cell
transplantation (HCT) and its improvement has led to
increase in the number of long-term survivors post HCT. We
have assessed risks of late mortality and causes of death
among long term survivors after allogeneic hematopoietic
stem cell transplantation (HCT).
Patients and Methods: 10,512 recipients of ﬁrst allogeneic
HCT for hematological diseases, who were relapse-free
